CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

April 1, 2026 · Phase 3 readout

VRDN Phase 3 readout: a negative outcome, -6.5%

On April 1, 2026, VRDN-003 — Viridian Therapeutics, Inc. (Thyroid Eye Disease) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -6.5% in the window around the event.

The move

$18.75
1d before
$17.53
Event day
$17.00
1d after
$17.20
5d after

Pre-catalyst setup

-3.5%
30-day run-up
11922%
30-day volatility
4.9×
volume spike